Experienced Biopharmaceutical Executive Steve Glover Joins Insmed; Will Lead Development of Follow-on Biologics

    RICHMOND, VA., June 25 /CNW/ - Insmed Inc. (Nasdaq:  INSM) today announced
that Steve Glover, 48, has joined Insmed's management team as President of the
newly formed Follow-on Biologics business, effective June 22, 2007. Mr. Glover
will be responsible for leading the development of Insmed's follow-on
biologics capability and its emerging portfolio of biogeneric/biosimilar

    Mr. Glover brings nearly 25 years of business experience in
bio-pharmaceuticals and life sciences to his new position. Prior to joining
Insmed, he held the position of Senior Vice President and General Manager at
Andrx Laboratories and Andrx Therapeutics, both divisions of Andrx
Corporation. He earlier held multiple sales, marketing and operational roles
at Hoffman LaRoche, Amgen Inc. and IMS Health. His strategic and operational
experience, which covers most therapeutic classes of biopharmaceuticals,
includes strategic planning, corporate development, operations management,
product development, product marketing and sales management.

    Mr. Glover commented, "I am excited to join the talented management team
that Insmed has assembled -- a team able to leverage Insmed's advanced
knowledge of biologics development, its manufacturing capability, and its
skilled scientific and technical workforce to make it the first U.S.-based
biotechnology company to develop a comprehensive portfolio of follow-on
biologics. This is an organization that knows the drug industry is on the
threshold of its second generic revolution."

    Dr. Geoffrey Allan, President and Chief Executive Officer of Insmed,
commented, "We are looking forward to benefiting from Steve's extensive
leadership experience in the bio-pharmaceutical and life sciences sectors. His
expertise will be instrumental in providing the strategic direction and
tactical capability to take full advantage of our unique combination of
protein know-how and drug approval skills. He will play a pivotal role in our
follow-on biologics strategy, which together with the development of our
approved flagship product IPLEX(TM) in niche markets, forms a dual-path
approach for success."

    About Insmed

    Insmed is a bio-pharmaceutical company focused on the development and
approval of drugs for the treatment of metabolic diseases with unmet medical
needs. For more information, please visit www.insmed.com. To be added to
Insmed's investor lists, please contact Haris Tajyar at htajyar@irintl.com or
at 818-382-9702.

    Forward-Looking Statements

    This release contains forward-looking statements which are made pursuant
to provisions of Section 21E of the Securities Exchange Act of 1934. Investors
are cautioned that such statements in this release, including statements
relating to planned clinical study design, regulatory and business strategies,
plans and objectives of management, and growth opportunities for existing or
proposed products, constitute forward-looking statements which involve risks
and uncertainties that could cause actual results to differ materially from
those anticipated by the forward-looking statements. The risks and
uncertainties include, without limitation, risks that product candidates may
fail in the clinic or may not be successfully marketed or manufactured, the
Company may lack financial resources to complete development of product
candidates, the FDA may interpret the results of studies differently than the
Company, competing products may be more successful, demand for new
pharmaceutical products may decrease, the bio-pharmaceutical industry may
experience negative market trends, and other risks and challenges detailed in
the Company's filings with the U.S. Securities and Exchange Commission,
including the Company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 2007. Readers are cautioned not to place undue reliance on any
forward-looking statements which speak only as of the date of this release.
The Company undertakes no obligation to publicly release the results of any
revisions to these forward-looking statements that may be made to reflect
events or circumstances that occur after the date of this release or to
reflect the occurrence of unanticipated events.

For further information:

For further information: Investor Relations International Haris Tajyar,
818-382-9702 htajyar@irintl.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890